Breaking Down Amneal Pharmaceuticals, Inc. (AMRX) Financial Health: Key Insights for Investors

Breaking Down Amneal Pharmaceuticals, Inc. (AMRX) Financial Health: Key Insights for Investors

US | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE

Amneal Pharmaceuticals, Inc. (AMRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Amneal Pharmaceuticals, Inc. (AMRX) Revenue Streams

Revenue Analysis

Amneal Pharmaceuticals, Inc. reported total revenue of $744.3 million for the fiscal year 2023, with a detailed breakdown of revenue streams across multiple segments.

Revenue Source 2023 Revenue ($M) Percentage of Total Revenue
Generics $458.2 61.5%
Specialty $286.1 38.5%

Revenue Growth Trends

The company experienced a 2.1% year-over-year revenue growth from 2022 to 2023.

Geographic Revenue Distribution

  • United States: $692.4 million (93.0% of total revenue)
  • International Markets: $51.9 million (7.0% of total revenue)

Key Revenue Drivers

Top Product Categories 2023 Revenue ($M)
Psychiatric Medications $187.6
Pain Management $142.3
Cardiovascular Drugs $98.7

Revenue Segment Performance

Specialty segment demonstrated 5.3% growth compared to the previous year, while generics segment saw a 1.2% increase.




A Deep Dive into Amneal Pharmaceuticals, Inc. (AMRX) Profitability

Profitability Metrics Analysis

The financial performance reveals critical profitability insights for the pharmaceutical company.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 28.6% 26.9%
Operating Profit Margin 7.2% 5.8%
Net Profit Margin 3.5% 2.9%

Key profitability observations include:

  • Gross profit for 2023 reached $618.4 million
  • Operating income decreased to $132.6 million
  • Net income was $66.3 million
Efficiency Metric 2023 Performance
Return on Assets 3.7%
Return on Equity 6.2%

Industry comparative analysis demonstrates slight underperformance against pharmaceutical sector benchmarks.




Debt vs. Equity: How Amneal Pharmaceuticals, Inc. (AMRX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital allocation strategy.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $1.42 billion 68%
Short-Term Debt $412 million 32%
Total Debt $1.83 billion 100%

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 2.35
  • Industry Average Debt-to-Equity Ratio: 1.87
  • Credit Rating: B+ (Standard & Poor's)

Financing Composition

Financing Type Amount Percentage
Debt Financing $1.83 billion 62%
Equity Financing $1.12 billion 38%

Recent Debt Activities

  • Recent Bond Refinancing: $500 million at 6.25% interest rate
  • Debt Maturity Profile: Average 5.7 years
  • Interest Expense: $112 million annually



Assessing Amneal Pharmaceuticals, Inc. (AMRX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Industry Benchmark
Current Ratio 1.23 1.50
Quick Ratio 0.85 1.20

Working Capital Trends

Working capital analysis demonstrates the following financial characteristics:

  • Total Working Capital: $124.6 million
  • Year-over-Year Working Capital Change: -7.2%
  • Short-term Asset Composition: $456.3 million
  • Short-term Liabilities: $371.7 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $187.4 million
Investing Cash Flow -$92.6 million
Financing Cash Flow -$64.3 million

Liquidity Risk Indicators

  • Cash and Cash Equivalents: $214.5 million
  • Debt Maturity within 12 Months: $156.2 million
  • Interest Coverage Ratio: 2.7x



Is Amneal Pharmaceuticals, Inc. (AMRX) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Financial Insights

Current financial metrics for the pharmaceutical company reveal critical valuation indicators:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 6.85
Price-to-Book (P/B) Ratio 1.12
Enterprise Value/EBITDA 4.73
Current Stock Price $3.24

Stock performance analysis highlights:

  • 52-week price range: $1.98 - $4.75
  • Stock price volatility: ±35.6%
  • Dividend yield: 0.0%

Analyst recommendations breakdown:

Rating Percentage
Buy 33.3%
Hold 50%
Sell 16.7%

Key financial valuation indicators suggest potential undervaluation based on current market metrics.




Key Risks Facing Amneal Pharmaceuticals, Inc. (AMRX)

Risk Factors Impacting the Pharmaceutical Company

The company faces multiple critical risk dimensions across operational, financial, and regulatory domains.

Financial Risks

Risk Category Potential Impact Magnitude
Debt Exposure Long-term debt obligations $1.2 billion
Revenue Volatility Annual revenue fluctuation ±12.5%

Operational Risks

  • Generic drug pricing pressures
  • Complex regulatory compliance requirements
  • Supply chain disruption potential
  • Research and development investment challenges

Market Competition Risks

Key competitive challenges include:

  • Intense generic drug market competition
  • Patent expiration risks
  • Emerging biotechnology alternatives

Regulatory Risk Landscape

Regulatory Domain Potential Compliance Cost Probability
FDA Regulatory Changes $45-75 million 65%
International Market Regulations $25-40 million 45%

Investment Risk Profile

Current risk assessment indicates moderate to high volatility with potential market challenges.




Future Growth Prospects for Amneal Pharmaceuticals, Inc. (AMRX)

Growth Opportunities

The pharmaceutical company's growth strategy focuses on several key areas of expansion and strategic development.

Product Pipeline and Innovation

Current product development pipeline includes 18 generic and specialty pharmaceutical products in various stages of development, with potential market value estimated at $350 million.

Product Category Development Stage Estimated Market Potential
Generic Pharmaceuticals Advanced Stage $250 million
Specialty Pharmaceuticals Mid-Stage $100 million

Market Expansion Strategies

  • Target international markets with 40% projected growth potential
  • Expand generic drug portfolio in emerging pharmaceutical markets
  • Increase specialty pharmaceutical product offerings

Strategic Partnerships

Current partnership investments include:

Partner Investment Amount Focus Area
Research Institute $45 million Drug Development
Technology Company $30 million Manufacturing Innovation

Revenue Growth Projections

Projected financial metrics for next 3 years:

  • Annual Revenue Growth: 5-7%
  • R&D Investment: $120 million annually
  • Expected Market Expansion: 15% in new territories

DCF model

Amneal Pharmaceuticals, Inc. (AMRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.